XML 47 R37.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Data (Tables)
9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Schedule of Significant Segment Expenses The Company has identified the following
significant segment expenses (SSEs) due to their relevance to the overall consolidated operating results (in thousands):
Three months ended September 30,Nine months ended September 30,
2025202420252024
Net sales from external customers$154,558 $145,165 $453,882 $360,351 
Significant segment expenses:
Materials62,581 61,503 186,457 157,946 
Salaries and Benefits46,984 38,936 133,857 94,122 
Depreciation and amortization4,874 4,027 14,227 10,058 
Interest expense, net2,393 3,475 7,873 4,683 
Other segment items (a)16,662 16,005 48,497 39,616 
Income before income tax provision21,064 21,219 62,971 53,926 
Income tax provision4,681 4,858 12,224 11,320 
Segment net income$16,383 $16,361 $50,747 $42,606 
Segment total assets (b)$652,821 
(a)Other segment items include (production overhead, stock compensation, professional fees, and other SG&A expenses).
(b)See Condensed Consolidated Balance Sheet for details.
Schedule of Revenue by Major Customers by Reporting Segments
The Company’s products are primarily sold to customers within the Medical and Non-medical markets. Sales by market for the three and nine months ended September 30, 2025 and 2024 are as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
20252024 (a)20252024 (a)
MarketNet Sales%Net Sales%Net Sales%Net Sales%
Medical$142,358 92.1%$132,623 91.4%$417,107 91.9%$318,079 88.3%
Non-medical12,200 7.9%12,542 8.6%36,775 8.1%42,272 11.7%
Net Sales$154,558 100.0%$145,165 100.0%$453,882 100.0%$360,351 100.0%
(a)Note – This table has been updated to conform to the current year presentation.